China Pharma subsidiary acquires ophthalmic oxygen therapy patent rights for $2.1M in stock

CHINA PHARMA HOLDINGS, INC.

Hainan Helpson acquires utility model patent (ZL 2022 2 0394857.6) and invention patent application for ophthalmic oxygen enriched atomization device from Chengdu Bonier.
Transfer price: RMB 15M (~$2.1M) paid via 11.1M CPHI shares at $0.1349/share within 10 days under Regulation S exemption.
Bonier provides 10-year technical services including product R&D, registration, and must secure Class II medical device registration within one year.
Service fee: 15% of net profit from product sales annually for 10 years, contingent on invention patent grant; if not granted, no service fee owed.
Stock issuance is unregistered and exempt under Regulation S; shares to a non-U.S. person in an offshore transaction.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CHINA PHARMA HOLDINGS, INC. entered into Technology Transfer Contract with Chengdu Bonier Medical Technology Development Co., Ltd valued at RMB 15 million, approximately $2.1 million (effective 2022-11-28).

Action: entry
Agreement: asset purchase
Counterparty: Chengdu Bonier Medical Technology Development Co., Ltd
Value: RMB 15 million, approximately $2.1 million
Effective: 2022-11-28

Exact text from the filing

On November 28, 2022, Hainan Helpson Medical & Biotechnology Co., Ltd (“Helpson”), a wholly owned subsidiary of China Pharma Holdings, Inc. (the “Company”), entered into a Technology Transfer Contract (the “Agreement”) with Chengdu Bonier Medical Technology Development Co., Ltd (“Bonier”).

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

CHINA PHARMA HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-22-077369

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.